InMed Pharmaceuticals Inc. Form SCHEDULE 13D — Nov 12, 2026
Fairmount Funds Management, Fairmount Healthcare Fund II L.P., Peter Harwin and Tomas Kiselak filed a Schedule 13D disclosing beneficial ownership of 10,555,507 shares, or 19.99%, of Mentari Therapeutics' common stock as of November 6, 2026. The stake stems from Fairmount's multi-stage backing of Mentari, including $50.0 million of 12% convertible notes and participation in an approximately $490.0 million pre-closing financing, culminating in the November 6, 2026 reverse merger in which InMed Pharmaceuticals became Mentari Therapeutics via a 1-for-10 consolidation and Nevada redomestication.
Key figures
- Shares Owned
- 10555507
- Percent Owned
- 19.99%
- Shares Outstanding
- 52813914
- Lockup period
- 180 days after First Effective Time
- Common stock purchase price
- $119,999,263 (including Convertible Notes principal and accrued interest contributed in the Mentari Pre-Closing Financing)
- Convertible notes principal
- $50.0 million at 12% interest
- Reverse consolidation ratio
- 1-for-10
- Preclosing financing commitment
- ~$490.0 million (including $52.7 million of Convertible Notes principal and accrued interest)
- Series a preferred purchase price
- $200,000
- Shares issuable on series a conversion
- 4013000
- Shares issuable on prefunded warrant exercise
- 1468222
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.